marketing wars over the new sleeping pills

You'll see marketing wars over the new sleeping pills... Lunesta, Rozerem, Ambien CR, and then indiplon next year.

Lunesta (eszopiclone) is making a big splash now to get a head start. It's the first one approved for long-term use...but it has a bitter aftertaste in up to 30% of patients.

Rozerem (ro-ZER-um) will be out this month. It's the first in a new class...melatonin receptor agonists.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote